Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Foliq is an oral folic acid supplement developed and marketed by ADP Pharma Corporation. It contains folic acid, a small molecule vitamin (B9) that is essential for various metabolic processes. Once ingested, folic acid is reduced in the body to tetrahydrofolate, which serves as a critical coenzyme for the synthesis of purine and pyrimidine nucleotides, thereby supporting DNA synthesis and cellular division. Foliq is primarily indicated for the treatment and prevention of folate deficiency states, megaloblastic anemia, and for use in pregnant women or women of child-bearing potential to protect against neural tube defects in their offspring. The product is formulated as a capsule for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Foliq.